Differential musculoskeletal outcome reporting in patients receiving bempedoic acid or atorvastatin: a disproportionality analysis using the EudraVigilance database
Using a Registry-based approach, we found increased odds of muscle-related ADR reports in BA recipients compared to ATO, although characterized by more favourable clinical outcomes. It is suggested to pay increased attention to consider drug-related causes of muscle symptoms when BA is used, particularly when in combination with statins.
Authors
- Michela Foschiatti
- Michele Gringeri (ORCID: https://orcid.org/0000-0002-2322-9794)
- Elena Gentile
- Danilo Menichelli (ORCID: https://orcid.org/0000-0001-9467-5903)
- Diego Fornasari (ORCID: https://orcid.org/0000-0002-9668-3103)
- Gianluca Gazzaniga (ORCID: https://orcid.org/0000-0003-0648-3309)
- Luca De Toni (ORCID: https://orcid.org/0000-0003-4958-5217)
- Stefano D’Onghia (ORCID: https://orcid.org/0000-0002-5174-7513)
- Marco Scatigna
- Filomena Valentino
- Antonio Romio
- Arianna Pani
- Daniele Pastori
- Chiara Galuppi
- Stefano Grosdani
Institutions
- University of Padua (IT)
- University of Milan (IT)
- Istituto Neurologico Mediterraneo (IT)
- Centro Cardiologico Monzino (IT)
- European School of Oncology (IT)
- European Institute of Oncology (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.3389/fphar.2025.1736657
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Padova